Engineered Cell Implants for Long-Term Immune-Evasive Therapy

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing cell-based therapies for chronic and genetic diseases face challenges in maintaining therapeutic substance production over extended periods without triggering a host immune response.

Innovation Solution

Engineered mammalian cells with reduced MHC class I and II protein complexes and inflammatory cytokines or pro-fibrotic factors, combined with implantable elements to mitigate the foreign body response, allowing sustained therapeutic agent delivery.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If cells are implanted to produce therapeutic substances, then therapeutic effect is improved, but host immune response is triggered

Engineering Contradiction:

Improvetherapeutic effectVSAvoidhost immune response

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses an implantable device as an intermediary barrier between the engineered cells and the host immune system. The device encapsulates the cells, allowing therapeutic substances to pass through while preventing immune cells from directly contacting and attacking the engineered cells, thus resolving the contradiction between maintaining therapeutic effect and avoiding immune rejection

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent modifies the expression levels of MHC class I and II proteins on the engineered cells by changing the genetic parameters (reducing or knocking out these proteins). This parameter change makes the cells less recognizable to the host immune system while maintaining their therapeutic function, thereby resolving the contradiction between therapeutic effectiveness and immune evasion

Inventive Principle:

Principle #35Parameter changes

2Duration of action of stationary object

If cells are engineered to produce therapeutic substances continuously, then duration of therapy is improved, but immune response and foreign body reaction increase

Engineering Contradiction:

Improveduration of therapeutic substance productionVSAvoidforeign body response

Core Design Contradiction:

Duration of action of stationary objectVSObject-affected harmful factors

Solution Approach 1:

The patent segments the system into two distinct components: the engineered cells that produce therapeutic substances and the implantable device that provides protection. This segmentation allows the cells to focus on therapeutic production while the device handles immune protection, enabling long-term therapy without excessive immune response

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The implantable device serves as a protective intermediary that extends the survival time of engineered cells by shielding them from immune attacks. This intermediary structure enables continuous therapeutic substance production over months or years while minimizing foreign body response through its design features

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS20260102435A1Engineered cells and implantable elements for treatment of disease

Publication Date: 2026.04.16 SIGILON THERAPEUTICS INC

AI summary

Described herein are engineered mammalian cells comprising a reduction in the level or function of one or more of a major histocompatibility complex (MHC) class I protein complex component, optionally, a MHC class II protein complex component and/or CIITA, as well as one of an inflammatory cytokine and a pro-fibrotic factor, and methods of making and using the same.